Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) Brilliant Violet 605 Anti-mouse CD19 Antibody     Product Data Sheet (PDF)    
Brilliant Violet 605™ Anti-mouse CD19 Antibody
1177695 125 µl $195.00       
1177700 50 µg $265.00       
Clone: 6D5
Isotype: Rat IgG2a, κ
Reactivity: Mouse
Immunogen: Mouse CD19-expressing K562 human erythroleukemia cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 605™ and unconjugated antibody.
Concentration: µg sizes: 0.2 mg/ml
µl sizes: lot-specific (please contact technical support for concentration and total µg amount)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:

FC - Quality tested

Application Notes:

Additional reported applications (for the relevant formats) include: immunofluorescence7.

Recommended Usage:

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is ≤5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application References:

1. Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
2. Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
3. Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
4. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
5. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
6. Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
7. Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
8. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
9. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
10. Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
11. Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed

C57BL/6 mouse splenocytes were stained

C57BL/6 mouse splenocytes were stained with CD19 (clone 6D5) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).



Description:

CD19 is a 95 kD glycoprotein also known as B4. It is a member of the Ig superfamily, expressed on all pro-B to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19. CD19, in association with CD21 and CD81, forms a molecular complex integral to B cell activation.

Other Names: B4
Structure: Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution: Pro-B cells to mature B cells (during development), follicular dendritic cells
Function: Modulates B cell activation and differentiation
Ligand Receptor: CD21, CD81, Leu-13
Antigen References:

1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.